Update on Biologics Litigation and IPRs

October 13, 2016

As the popularity of biosimilars continues to grow in the United States, biosimilar and biologics manufacturers have begun testing the bounds of the BPCIA statute in district court litigation. In addition, biosimilar manufacturers have also turned to IPR proceedings to challenge patents covering biologic drugs.

Fish attorneys Gwilym Attwell and Michael Amon presented the following recent developments:

  • Recent district court cases and their impact on the biosimilars industry
  • IPRs challenging biologic patents
  • Strategies for biologics litigation

Gwilym Attwell, Principal
Michael Amon, Principal